Joslin Diabetes Center is the only diabetes institution in the world that goes beyond a single focus. With efforts in these three critical areas, a synergy develops: researchers, clinicians and educators collaborate in ways that produce cutting-edge scientific discovery, unique clinical care models and pioneering educational strategies. This one-of-a-kind framework has an impact on people with diabetes locally, nationally and across the globe.

Hyperglycemia and Dyslipidemia in Diabetes: Interrelationships and Interventions


Statement of Need
Considering the potential personal and financial impact of widespread vascular disease, today's clinical challenge is not only to reduce hyperglycemia, but also to blunt the cardiovascular impact through therapeutic targeting of the many cardiovascular risk factors. Timely and aggressive intervention is needed to target recommended metabolic control levels. Careful data analysis and interpretation should result in the adoption of more aggressive treatment plans in line with recent recommendations for stricter A1C and LDL-C treatment goals in the at-risk patient.

Clinicians are often faced with complex metabolic scenarios, such as individuals who are already using multiple medications, yet A1C or LDL-C levels are still not quite at target, or individuals in need of treatment for type 2 diabetes and/or dyslipidemia with contraindications for, or a history of adverse events with, some medications. Yet, there is a strong imperative not to let these obstacles prevent achievement of clinical goals. Fortunately, the etiologic interrelationships among various risk factors result in therapeutic overlap among therapies that allows multiple treatment approaches to be considered. This approach will be particularly effective in overcoming these treatment obstacles and challenges. This educational activity presents the array of data supporting the early and aggressive treatment of hyperglycemia and dyslipidemia and evaluates multiple therapeutic approaches to these conditions with the goal of achieving therapeutic targets aimed at reducing the incidence of cardiovascular disease.

Target Audience

This CME accredited symposium has been developed for primary care physicians and other healthcare professionals who treat patients with diabetes and its related conditions. There is no fee to attend this activity. However, space is limited, and reservations will be accepted on a first-come, first-served basis. Only clinicians can be admitted. Guests who are not clinicians cannot be accommodated.